BridgeBio Pharma, Inc.
HealthcareNASDAQ:BBIO · NASDAQ Global Select
-$0.75 today
Vol 1.47M · Avg 2.47M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
35.1%
avg -53.8%
ROIC
-108.5%
avg -79.7%
ROA
-77.9%
avg -61.2%
Analysis
ROE is currently the strongest return metric at 35.1% versus its period average of -53.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Neil Kumar | Co-Founder, Chief Executive Officer & Director | $2.46M | — | 47 | $4.32M | 2.20% |
Uma Sinha | Chief Scientific Officer | $1.31M | — | 68 | $10,832.00 | <0.01% |
Thomas Trimarchi | Chief Financial Officer & President | $1.23M | — | 41 | $362,389.00 | 0.19% |
Charles J. Homcy | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director | $574,167.00 | — | 78 | $916,674.00 | 0.47% |
Frank McCormick | Co-Founder, Chairman of Oncology & Director | $550,000.00 | — | 76 | $731,970.00 | 0.37% |
Richard H. Scheller | Chairman of Research & Development | $509,622.00 | — | 73 | $55,126.00 | 0.03% |
Jonathan C. Fox FACC | President & Chief Medical Officer of Cardiovascular and Renal Diseases | — | — | 69 | — | — |
Matthew Outten | Chief Commercial Officer | — | — | 52 | — | — |
Maricel Apuli | Chief Accounting Officer | — | — | 49 | $129,401.00 | 0.07% |
Eric Michael David | Chief Executive Officer of Gene Therapy | — | — | 54 | $8,425.00 | <0.01% |
Eli Wallace | Chief Scientific Officer of Oncology | — | — | 59 | — | — |
Adora Ndu | Chief Regulatory Affairs Officer | — | — | 45 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
146
$94.46M
Net Sentiment
$94.46M
Net selling
Most Active
Kumar Neil
111 transactions
1–10 of 146
Analysis
Insiders reported 0 buys worth $0.00 and 146 sells worth $94.46M over the last 12 months. That adds up to net selling of $94.46M. Kumar Neil was the most active insider with 111 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | +58.7% (9yr)8 analysts |
| Net Income | N/A | N/A | N/A | N/A8 analysts |
| EBIT | N/A | N/A | N/A | N/A8 analysts |
Analysis
Forward estimates point to Revenue at +58.7% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.71B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.61B
Moderna, Inc.
NASDAQ:MRNA
$19.80B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.48B
Ascendis Pharma A/S
NASDAQ:ASND
$13.47B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.11B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.86B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.81B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Who manages BBIO?
BridgeBio Pharma, Inc. (BBIO) lists 12 active executives. The top listed executive is Neil Kumar, Co-Founder, Chief Executive Officer & Director.
Are BBIO insiders buying or selling?
Recent insider activity shows net selling of $107.30M.
Explore More
Continue the stock analysis
Jump to another research area for this company.